PhRMA states that the chilling effect is profound.
“If you’re a patient … it’s definitely not a trivial issue,” Zoldersma said.
Others say drug development is unlikely to shrink. Dr. Stephen Pearson, director of the nonprofit Institute for Clinical Economic Review (ICER) in Boston, said that valuable medicines will lead the way, but drugs of lesser benefit will follow a more difficult path. .. Research institutes recommend prices based on effectiveness.
“The big debate is whether the government keeps a finger on the process, and somehow it hinders innovation,” Pearson said. “By making payments smart, we can innovate even better.”
Industry insider Zoldersma said: “ICER’s Steve Pearson never discovered or brought to market a cure or a cure.”
“The level of exaggeration we hear in this current drug debate shows that the industry is very concerned,” said Juliette Kubansky, a Medicare expert at the nonpartisan Kaiser Family Foundation. ..
One of the industry’s biggest dissent is that the House bill would use lower prices as a standard for Medicare in other developed countries. The Trump administration has tried similar ideas with different sets of Medicare drugs. Pharmaceutical companies say patients in the United States may have to wait longer than they are used to waiting for a new drug to pass.
Restrictions on Medicare drug price negotiations under pressure | Government. & Politics
Source Links Restrictions on Medicare Drug Price Negotiations Under Pressure | Government. & Politics